Calcitonin gene-related peptide: An update on the biology

Current Opinion in Neurology

Volumn 22, Issue 3, 2009, Pages 241-246

  Recober, Ana ^a,b   Russo, Andrew F ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Calcitonin gene related peptide (CGRP); CGRP receptor; Migraine; Therapy

Indexed keywords

BMS 694153; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; MK 0974; OLCEGEPANT; TELCAGEPANT; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; MIGRAINE; NONHUMAN; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL MARKERS; CALCITONIN GENE-RELATED PEPTIDE; HUMANS; MIGRAINE DISORDERS; PROTEIN BINDING; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE;

EID: 67049108842     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/WCO.0b013e32832b2427     Document Type: Review

References (62)

1. Arulmani U, Maassenvandenbrink A, Villalon CM, et al. Caloitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol 2004; 500:315-330.
2. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104-1110.
3. Goadsby PJ. Recent advances in the diagnosis and management of migraine. BMJ 2006; 332:25-29.
4. Edvinsson L Blockade of CGRP receptors in the intracranial vasculature: a new target in the treatment of headache. Cephalalgia 2004; 24:611-622.
5. de Prado BM, Russo AF. CGRP receptor antagonists: a new frontier of antimigraine medications. Drug Discov Today 2006; 3:593-597.
6. Durham PL. Calcitonin gene-related peptide (CGRP) and migraine. Headache 2006; 46 (Suppl 1):S3-S8.
7. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neural 1990; 28:183-187.
8. Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 2003; 106: 461-470.
9. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neural 1993; 33:48-56.
10. Tvedskov JF, Lipka K, Ashina M, et al. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neural 2005; 58:561-568.
11. Ashina M, Bendtsen L, Jensen R, et al. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 2000; 86:133-138.
12. Fusayasu E, Kowa H, Takeshima T, et al. Increased plasma substance P and CGRP levels, and high ACE activity in migraineurs during headache-free periods. Pain 2007; 128:209-214.
13. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54-61.
14. Petersen KA, Lassen LH, Birk S, et al. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005; 77:202-213.
15. Hansen JM, Thomsen LL, Olesen J, et al. Calcitonin gene-related peptide does not cause the familial hemiplegic migraine phenotype. Neurology 2008; 71:841-847. This study shows that CGRP does not cause an aura or delayed headache in individuals with familial hemiplegic migraine.
16. Hansen JM, Thomsen LL, Olesen J, et al. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia 2008; 28:496-505.
17. Hansen JM, Thomsen LL, Marconi R, et al. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia 2008; 28:367-375.
18. Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther 2008; 120:157-171. Comprehensive review of the role of nitric oxide in primary headaches with references to interactions of the CGRP and nitric oxide pathways in headache pathophysiology.
19. Edvinsson ML, Edvinsson L Comparison of CGRP and NO responses in the human peripheral microcirculation of migraine and control subjects. Cephalalgia 2008; 28:563-566. This study shows that peripheral microcirculation in migraineurs is not hypersensitive to CGRP and nitric oxide, suggesting that central effects of CGRP may be more relevant in migraine.
20. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008; 70:1304-1312. Phase II clinical trial of the oral CGRP antagonist telcagepant showing effectiveness and tolerability in comparison with a triptan.
21. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008; 372:2115-2123. Phase III clinical trial of the oral CGRP antagonist telcagepant showing effectiveness and tolerability in comparison with a triptan.
22. Giniatullin R, Nistri A, Fabbretti E. Molecular mechanisms of sensitization of pain-transducing P2X3 receptors by the migraine mediators CGRP and NGF. Mol Neurobiol 2008; 37:83-90. Review of P2X3 receptors in chronic pain and possible role in migraine.
23. Simonetti M, Giniatullin R, Fabbretti E. Mechanisms mediating the en-hanced gene transcription of P2X3 receptor by calcitonin gene-related peptide in trigeminal sensory neurons. J Biol Chem 2008; 283:18743-18752. This study describes the effect of CGRP on two target genes relevant to migraine, which may help explain the mechanism underlying the delayed onset of headache following CGRP injection.
24. Davis CD, Xu C. The tortuous road to an ideal CGRP function blocker for the treatment of migraine. CurrTop Med Chem 2008; 8:1468-1479.
25. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000; 129:420-423.
26. Recober A, Russo AF. Olcegepant, a nonpeptide CGRP1 antagonist for migraine treatment. IDrugs 2007; 10:566-574.
27. Goadsby PJ. Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era? Neurology 2008; 70:1300-1301. Editorial discussing CGRP antagonists in migraine therapy.
28. Edvinsson L. CGRP-receptor antagonism in migraine treatment. Lancet 2008; 372:2089-2090. Comment discussing CGRP antagonists in migraine therapy.
29. Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological character-ization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl) -piperidine-1-carbox amide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J Pharmacol Exp Ther 2008; 324:416-421. This is a detailed description of the pharmacological characteristics of telcagepant.
30. Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of nonpeptide CGRP receptor antagonists. J Biol Chem 2002; 277:14294-14298.
31. Zhang Z, Winborn CS, Marquez de Prado B, et al. Sensitization of calcitonin gene-related peptide receptors by receptor activity-modifying protein-1 in the trigeminal ganglion. J Neurosci 2007; 27:2693-2703.
32. Koulchitsky S, Fischer M, Messlinger K. Calcitonin gene-related peptide receptor inhibition reduces neuronal activity induced by prolonged increase in nitric oxide in the rat spinal trigeminal nucleus. Cephalalgia 2009; 29:408-417. This study demonstrates how a CGRP receptor antagonist can prevent nitric oxide-induced activation of the spinal trigeminal nucleus and suggests possible shared mechanisms between nitric oxide and CGRP.
33. Degnan AP, Chaturvedula PV, Conway CM, ef al. Discovery of (R)-4-(8-fluoro-2-oxo-1,2-dihydroquinazolin-3(4H)-yl)-N-(3-(7-methyl-1 H-in dazol-5-yl)-1 -oxo-1 -(4-(piperidin-1 -yljpiperidin-1 -yl)propan-2-yl) piperidine-1 -carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 2008; 51:4858-4861.
34. Nguyen DN, Paone DV, Shaw AW, et al. Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template. Bioorg Med Chem Lett 2008; 18:755-758.
35. Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008; 9:5-12.
36. Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache 2008; 48:1259-1268.
37. Farinelli I, Missori S, Martelletti P. Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class. Expert Rev Neurother 2008; 8:1347-1354.
38. Benemei S, Nicoletti P, Capone JG, et al. CGRP receptors in the control of pain and inflammation. Curr Opin Pharmacol 2009; 9:9-14.
39. Edvinsson L. Novel migraine therapy with calcitonin gene-regulated peptide receptor antagonists. Expert Opin Ther Targets 2007; 11:1179-1188. Comprehensive review of CGRP antagonists in migraine therapy.
40. Edvinsson L. CGRP blockers in migraine therapy: where do they act? Br J Pharmacol 2008; 155:967-969. This review discusses the controversy regarding the site of action of CGRP receptor antagonists.
41. Lennerz JK, Ruhle V, Ceppa EP, et al. Calcitonin receptor-like receptor (CLR), receptor activity-modifying protein 1 (RAMP1), and calcitonin gene-related peptide (CGRP) immunoreactivity in the rat trigeminovascular system: differences between peripheral and central CGRP receptor distribution. J Comp Neural 2008; 507:1277-1299. This study is the first detailed analysis of the distribution of CGRP receptor components throughout the rat trigeminovascular system.
42. Marvizon JC, Perez OA, Song B, et al. Calcitonin receptor-like receptor and receptor activity modifying protein 1 in the rat dorsal horn: localization in glutamatergic presynaptic terminals containing opioids and adrenergic alpha2C receptors. Neuroscience 2007; 148:250-265. This study shows the distribution of the CGRP receptor in the rat dorsal horn.
43. Cottrell GS, Roosterman D, Marvizon JC, et al. Localization of calcitonin receptor-like receptor and receptor activity modifying protein 1 in enteric neurons, dorsal root ganglia, and the spinal cord of the rat. J Comp Neural 2005; 490:239-255.
44. Anderson LE, Seybold VS. Calcitonin gene-related peptide regulates gene transcription in primary afferent neurons. J Neurochem 2004; 91:1417-1429.
45. Harriott AM, Gold MS. Serotonin type 1D receptors (5HTR) are differentially distributed in nerve fibres innervating craniofacial tissues. Cephalalgia 2008; 28:933-944. This study addresses the distribution of serotonin type 1D receptors as a potential explanation for the specificity of triptans for headache versus other pain syndromes.
46. Zeller J, Poulsen KT, Sutton JE, et al. CGRP function-blocking antibodies inhibit neurogenic vasodilatation without affecting heart rate or arterial blood pressure in the rat. Br J Pharmacol 2008; 155:1093-1103. This study describes a complementary, but alternative strategy to CGRP receptor antagonists.
47. Denekas T, Troltzsch M, Vater A, et al. Inhibition of stimulated meningeal blood flow by a calcitonin gene-related peptide binding mirror-image RNA oligonu-cleotide. Br J Pharmacol 2006; 148:536-543.
48. Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and nonperfused rat middle cerebral artery. Br J Pharmacol 2007; 150:633-640. This study looks at the site of action of CGRP receptor antagonists, CGRP antibody and RNA-Spiegelmer on the vasculature.
49. Luykx J, Mason M, Ferrari MD, ef al. Are migraineurs at increased risk of adverse drug responses? A meta-analytic comparison of topiramate-related adverse drug reactions in epilepsy and migraine. Clin Pharmacol Ther 2009; 85:283-288.
50. Fan PC, Kuo PH, Chang SH, ef al. Plasma calcitonin gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia 2009 [Epub ahead of print]. This study found elevated levels of CGRP in migraineurs in a pediatric population.
51. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002; 54:233-246.
52. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther 2006; 109:173-197.
53. McLatchie LM, Fraser NJ, Main MJ, ef al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998; 393:333-339.
54. Hay DL, Christopoulos G, Christopoulos A, et al. Determinants of 1 -piper-idinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl] carbonyl]-pentyl]amino]-1-[(3,5-dibromo-4-hydroxyphenyl)methyl]-2-oxoethyl] -4-(1,4-dihydro-2-oxo-3(2 H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors-the role of receptor activity modifying protein 1. Mol Pharmacol 2006; 70:1984-1991.
55. Sexton PM, Poyner DR, Simms J, et al. Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 2009; 14:413-419. This review discusses the role of RAMPs as potential drug targets.
56. Kusano S, Kukimoto-Niino M, Akasaka R, et al. Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein Sci 2008; 17:1907-1914.
57. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004; 84:903-934.
58. Qi T, Christopoulos G, Bailey RJ, et al. Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function. Mol Pharmacol 2008; 74:1059-1071. This study identifies important residues of the RAMPs that may affect the CGRP receptor function.
59. Russo AF. Ramping it up: RAMP1 and the implications for migraine. Pharmacogenomics 2007; 8:687-690. This editorial discusses the potential roles of RAMP1 in migraine.
60. Toda M, Suzuki T, Hosono K, et al. Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide. Proc Natl Acad Sci U S A 2008; 105:13550-13555.
61. Huang R, Karve A, Shah I, et al. Deletion of the mouse alpha-calcitonin gene-related peptide gene increases the vulnerability of the heart to ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2008; 294:H1291-H1297.
62. Gonzalez-Alegre P, Paulson HL. Technology insight: therapeutic RNA interference: how far from the neurology clinic? Nat Clin Pract Neural 2007; 3:394-404.